THERAPY DOSSIER · th-0d6ea7c39e0b

Alpha-melanocyte-stimulating hormone, mesenchymal stem cells and cerebrolysin, given conventionally or as TiO2-nanowired formulations

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00004496 ↗PHASE1completed

Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure

Acute Renal Failure

Enrolment: 45 · Results not recorded

NCT06293664 ↗NAunknown

Physiological Impact of Alpha MSH on Glycemic Response to an OGTT in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Enrolment: 13 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 33223033 ↗2020Reported benefit

Concussive head injury exacerbates neuropathology of sleep deprivation: Superior neuroprotection by co-administration of TiO2-nanowired cerebrolysin, alpha-melanocyte-stimulating hormone, and mesenchymal stem cells.

RatTBIClosed-head / concussionAlpha-MSH 250 micrograms/kg conventional or 100 micrograms…

Model: Concussive head injury combined with 48 hours of sleep deprivation

Combined sleep deprivation and concussive head injury produced greater blood-brain barrier leakage and brain pathology than either insult alone, with lower alpha-MSH and BDNF and higher TNF-alpha. Combined alpha-MSH, mesenchymal stem cells and cerebrolysin were neuroprotective, and TiO2-nanowired d…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…